DDNews-2016 media kit.indd
Transcription
DDNews-2016 media kit.indd
2017 MEDIA KIT 2017 MEDIA KIT ddn-news.com ddncancer.com Covering the News of Pharma, Biotech & Life Science A global pharma readership: From publishing our first issue in April 2005, to celebrating our 13th year in 2017, DDNews is the only pharmaceutical publication to evolve from a “discovery” base to what we are today: a full service information resource covering the pharmaceutical and biopharmaceutical industry from Discovery through Clinical Trials. Our Editorial Departments reflect our editorial breadth and demonstrates our functional reach: Discovery R&D Preclinical Clinical Trials AREA OF FOCUS Target Identification Biomarker Discovery ■■ Lead Identification ■■ ■■ Drug Development Target Validation ■■ Lead Optimization ■■ ■■ Lead Optimization ■■ ADMET ■■ Phase I Phase II ■■ Phase III Our major news vehicles: Monthly Print Edition: Issued monthly to more than 39,000 global pharma professionals encompassing nearly every corner of the globe. DDNews focuses on delivering the news of technology and business, which keeps readers current and relevant in the ever changing pharmaceutical industry. DDNews Online: A twice-monthly e-newsletter that covers breaking business stories and recent significant research findings. DDNews website: A news portal that houses all our in-depth content, industry resources, product literature, white papers and archived print issues. DDNews Cancer Research News: The only independent website dedicated to reporting on the latest news of oncology research, trends and resources. In addition, a special RSS feed puts readers just one click away from up-to-the-minute cancer-related headlines. Global integrated marketing opportunities to fit every budget : MONTHLY NORTH AMERICA PRINT EDITION ■■ ■■ ■■ PHA RM A, DISCOVERY RESEARCH & DEVELOPME PRECLINICAL CLINICAL TRIALS 6 NT 12 16 & LIFE SCI ENC E JULY 2016 : VOLUME Answers about alp ha-synuclein PUBLISHE 12 : NUMBER 7 University of Pittsburgh team uncove rs the of alpha-synucle cause in Parkinson’s in toxicity late what we’re doing in the laboratory something that’s into going difference for people to make a meaningful affected by Parkinson’ disease. I believe s these findings will have a lot of impact in the munity. We couldn’tParkinson’s research comMedicine—for which of Pittsburgh School of support of APDA.” have done it without the Disease Associatio the American Parkinson n (APDA) was In Parkinson’s disease, partner—has revealed a funding contain large clumps the failing neurons sons why alpha-synu one of the major reaof the clein, protein a significant comsynuclein. Individual alphaponent of the Lewy s whose cells produce too much of the Parkinson’s disease, bodies that characterize protein, or a mutated proves have a high risk form, The findings appeared toxic to neurons. of developing Parkinson in Science Transladisease due to alpha-synu tional Medicine ’s in a clein’s toxicity. Alpha-synuclein binds to TOM20 paper titled “α-Synuclein MARKET NEWS and inhibits mitochond protein, but much is a naturally produced protein import EDITORIAL/COMMENTA 3 in Parkinson’s disease.” rial of the main culpritslike amyloid beta—one RY study’s lead investigato The PRODUCTS & SERVICES 10 r was Dr. J. Timothat, it was recently of Alzheimer’s disease thy Greenamyre, Love Family Professor LATE-BREAKING NEWS 45 by the brain as an discovered, is generated In work that Neurology in Pitt’s antibiotic—is not School of Medicine of on treatmentcould have a significant impact 46 in its normal form harmful director of the SPECIAL REPORT and of researchersof Parkinson’s disease, Pittsburgh Institute a team As Greenamyre and in normal amounts. at the University rodegenerative tells DDNews, Cell Biology: Sweeteni of Pittsburgh Diseases (PIND), for Neu- has found two ways “We really understand to prevent the who also that alpha-synu ng the pot 20 serves as the director Is improved understanding [alpha-synuclein’s] do not toxicity of the clein function; of APDA glycobiology causes. normal improved biologics? Center for Parkinson’ Advanced the university’s however, Pictured here the secret to is Cathedral of it—by virtue of if we make too much of Learning. PIND and a member s Disease Research at treatment our genetic makeup of the APDA Scientific s for this devastatin PLUS: response to environme or in Advisory Board. g disease,” Greenamyre remarked ntal toxins—it Special Focus on Zika can “It’s really exciting in a press release. change its structural characteris 42 “I’ve been involved that we have tics in ways a mechanism we in Parkinson’s research that make it toxic. By can target to createfound for more than 25 years, have genetic mutationsthe same token, if we and new go along, and make abnormal the more urgency the further I forms of the protein, it may be I feel to transtoxic.” Though BUSINESS & GOVERNMEN T POLICY TOOLS & TECHNOLOG Y 27 32 35 BY KELSEY KAUSTINEN PITTSBURGH— Some out of the University of the latest research 37 Next-generatio n mapping for genomic assemblies .................................................... Baring the bones .................................................... .........6 MuScreen comes .............12 on scene On the cutting edge...............................................................35 ............................................37 PITT CONTINUED Research & Development ■■ Clinical Trials ■■ Manufacturing ■■ Regulatory Business & Government 2 Approval Registration ■■ Manufacturing ■■ Regulatory Process ■■ Catalyst had thought all that remained for adequate and Firdapse to gain well-controlled FDA approval study, in addition but the company was one to providing was recently well-supported directed to do a follow-up study literature, by the FDA. One last study in LEMS Catalyst inches closer to FDA approval for Firdapse BY ZACK patients with Lambert-E ic syndrome (LEMS), aton myasthenANCHORS disabling autoimmu a rare, frequently ne neuromuscular CORAL GABLES, disorder announcing positive Fla.— Weeks after weaknessthat produces serious muscle 3 study of its drug results from a Phase dysfunctio and symptoms of autonomic n. Catalyst Pharmace candidate Firdapse, The initial Phase uticals is preparing for yet another ticenter, randomiz 3 study was a mulstudy of the drug. ed, double-bl follow-up research The placebo-co ind, is a somewhat pected hurdle that unex- 38 patientsntrolled withdrawal trial. All enrolled in the the U.S. Food and emerged as a result of initially study were Drug Administra treated with Firdapse (FDA) insistence tion’s by treatment followed with either additional positive that Catalyst submit cebo during a two-week Firdapse or plaresults from another adequate and randomization period. The trial well-controlled was designed so study in that the CATALYST CONTINUED ON PAGE 31 CREDIT: FDA Contract Services ON PAGE 9 Could microb e research tool iom revolutionize drug developm ent? The University of ■■ Luxembourg ‘breakthroug announces organ-on-a-ch’ HuMiX for the humanhip model gastrointestinal tract INTEGRATED WEBSITE ■■ ■■ ■■ ■■ ■■ BY JEFFREY BOULEY & RACHEL FLEHINGER LUXEMBO URG CITY, Luxembou rg— human microbiom The e potential therapeuti as an area of research for c value continues popularity and, to gain in that Luxembourg recently vein, the University of announced the publication of a research article nal Nature Communica in the scientific jouron the interaction tions based on research An organ-on-a-chip model for the human gastrointestinal tract could in the gut and the between microorganisms reduce reliance on animal do much to development of human body through the with better models and the artificial Human-M end up results, says the University bial X(cross)-ta icro- Luxembourg. Pictured of lk model, here is a researcher dealing with HuMiX represents or HuMiX. cell cultures. model for the human an organ-on-a-chip in vitro. The gastrointestinal and it has been tract, expected model and resulting insights developed to study are to help provide action between the inter- ing a better understand the microbiom e, the com- omeof whether changes in the gut’s munity of all microbial microbicause disease, or organisms that in and on our body if such live changes consequence of are a and the human the disease. host—all HUMIX CONTINUED ■■ INTERNATIONAL DIGITAL EDITION ON PAGE 15 Bi-weekly e-newsletter Custom Content Marketing 07.16 D SINCE 2005 CREDIT: UNIVERSITY Diagnostics Biomarker Discovery ■■ Assay Development ■■ Biomarker Validation BIO TEC H WHAT ’S INSID E DIAGNOSTICS CONTRACT SERVICES ■■ E-NEWSLETTERS ■■ OF PITTSBURGH DEPARTMENT DDNews’ circulation is focused on covering the global pharmaceutical and biopharmaceutical industry. While some readers are not employed by “big pharma”, these individuals work in the expanding arena of contract research services, universities, and government agencies like the CDC and NIH: all working on pharma from discovery through clinical trials. Print Circulation............................................................34,298 Digital/International Edition Circulation..................5,234 e-Newsletter Circulation.............................................82,000+ Whitepapers & Application Notes Research Portals Oncology News Online video library Podcasts CUSTOM E-MARKETING ■■ Custom html e-blasts 3 INDUSTRY TOTAL PERCENT OF TOTAL Pharmaceutical 17,799 45.0% Biopharmaceutical 9,005 22.8% Biotech 3,978 10.1% Consulting firms 457 1.2% Contract Research Manufacturing 1,068 2.7% Government 1,151 2.9% Clinical Research/Hospital/Medical Center 1,881 4.8% Private Research/Independent 949 2.4% University/College 3,099 7.8% Other 145 0.4% PRODUCTS USED TOTAL PERCENT OF TOTAL ADME/TOX 12,391 31.3% Assay Development 19,388 49.0% 1.2% Bioinformatics 18,717 47.3% 19,317 48.9% Circulation Demographic Analysis JOB TITLE Academic Department Head/Chair TOTAL 462 PERCENT OF TOTAL CEO/President/Executive 1,356 3.4% Cellular Analysis Consultant 361 0.9% Cell/Tissue Culture 18,608 47.1% 7.4% Chromatography 27,048 68.4% 14.6% Crystallography 18,377 46.5% 19,054 48.2% Group or Section Leader Lab Director/Lab Mgr./Dept. Mgr. 2,944 5,769 Principal Investigator 3,914 9.9% DNA Sequencing Production/Process Engineer 623 1.6% Electrophoresis 16,348 41.4% 2.6% Epigenetics 23,326 59.0% 5.8% Flow Cytometry 18,416 46.6% 20,038 50.7% Professor/Instructor Research Assistant/Grad Student/Post Doc 1,032 2,298 Research Director/VP of Research 3,209 8.1% Fluorescence Research Scientist 17,253 43.6% Gene Expression 18,279 46.2% 0.8% Genotyping 19,337 48.9% HPLC 20,677 52.3% 18,701 47.3% Other 311 FIELD & DISCIPLINE TOTAL PERCENT OF TOTAL HTS Image Analysis 17,799 45.0% Bioanalytical Chemistry 16,337 41.3% Immunology 15,638 39.6% Biochemistry 16,982 43.0% Label Free Detection 16,498 41.7% Cell Biology 16,757 42.4% Mass Spectroscopy 26,395 66.8% Clinical Diagnostics 14,798 37.4% Micro Arrays 17,201 43.5% Development/Manufacturing 13,631 34.5% Microplate Analysis 18,677 47.2% Genomics/Genetics 13,378 33.8% Nucleic Acid/ Oligos 17,900 45.3% Medicinal Organic Chemistry 16,806 42.5% PCR 19,243 48.7% Microbiology 14,998 37.9% qPCR 18,602 47.1% Molecular Biology 12,767 32.3% Protein Expression 17,928 45.4% Neuroscience 17,231 43.6% Proteomics 18,016 45.6% Oncology 13,385 33.9% Purification 18,580 47.0% Pharmacology 11,158 28.2% RNAi/siRNA 18,175 46.0% Proteomics/Protein Chemistry 7,825 19.8% Stem Cell 24,728 62.6% Toxicology 7,129 18.0% Translational Research 18,598 47.0% 4 5 Circulation Geographic Analysis NORTH AMERICA TOTAL PERCENT OF TOTAL Canada 428 1.1% United States 33,759 85.4% Mexico 111 0.3% 34,298 86.8% CENTRAL/SOUTH AMERICA TOTAL PERCENT OF TOTAL Argentina 20 0.1% Brazil 79 0.2% Chile 30 0.1% Colombia 10 0.0% Costa Rica 2 0.0% Ecuador 4 0.0% Nicaragua 5 0.0% Panama 3 0.0% Peru 11 0.0% Other 19 0.0% 183 0.5% ASIA/PACIFIC TOTAL PERCENT OF TOTAL Afghanistan 3 0.0% Australia 130 0.3% China 181 0.5% Hong Kong 77 0.2% India 407 1.0% Indonesia 21 0.1% Malaysia 109 0.3% EUROPE TOTAL PERCENT OF TOTAL Austria 56 0.1% New Zealand 27 0.1% Belgium 138 0.3% Philippines 20 0.1% Czech Republic 17 0.0% Republic of Korea 257 0.7% Denmark 71 0.2% Singapore 111 0.3% Finland 71 0.2% Taiwan 55 0.1% France 361 0.9% Thailand 31 0.1% Germany 380 1.0% Other 11 0.0% Greece 62 0.2% 1,440 3.6% Hungary 44 0.1% Ireland 66 0.2% Italy 192 0.5% AFRICA/MIDDLE EAST TOTAL PERCENT OF TOTAL Netherlands 129 0.3% Norway 28 0.1% Egypt 61 0.2% Poland 29 0.1% Iran 4 0.0% Portugal 32 0.1% Iraq 6 0.0% Russian Federation 15 0.0% Israel 41 0.1% Spain 201 0.5% Jordan 9 0.0% Sweden 128 0.3% Lebanon 2 0.0% Switzerland 173 0.4% Saudi Arabia 18 0.0% Turkey 20 0.1% South Africa 107 0.3% United Kingdom 1,120 2.8% Other 15 0.0% Other 15 0.0% 263 0.7% 3,348 8.5% 39,532 100% TOTAL * All USA copies are print edition, all others delivered digitally. 6 7 DDNews Circulation: Top 50 BioPharm/Biotech Companies Rank* Company 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Roche Gilead Sciences Amgen Teva Novo Nordisk Actavis/Allergan Merck KGaA Biogen Valeant Celgene Shire CSL Behring Grifols Sun Pharma UCB Regeneron Endo International Alexion Dr Reddy's Illumina Actelion Novozymes IPSEN United Therapeutics Jazz Vertex Medivation Biomarin Anacor Horizon Pharma Incyte Alkermes PDL Biopharma Emergent Acorda Therapeutics Biocon Amag Pharma Seattle Genetics The Medicines Co China Biologic Ionis Aegerion Nektar Therapeutics Pharmamar Genmab Spectrum Sciclone Pharma Bavarian Nordic Ariad Morphosys Source: HS&M Magazine 8 Print Subscribers e-News Subscribers Global HQ Base 922 706 1,085 300 151 160 251 422 30 325 78 23 10 89 37 154 128 28 18 17 30 19 4 88 11 316 19 35 53 47 12 69 51 105 18 18 20 15 29 14 22 85 50 4 4 27 23 2 4 6 2,163 881 2,145 918 284 286 287 1,231 64 594 257 184 23 188 217 249 259 42 56 76 110 26 10 128 32 612 98 65 150 111 32 225 93 129 40 119 34 60 50 26 80 145 91 8 9 58 55 9 15 14 Switzerland USA USA Israel Denmark USA Germany USA Canada USA England USA Spain India Belgium USA Ireland USA India USA Switzerland Denmark France USA Ireland USA USA USA USA USA USA Ireland USA USA USA India USA USA USA China USA USA USA Spain USA USA USA Denmark Spain Germany DDNews Circulation: Top 50 Pharma Companies Rank* Company 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Pfizer Novartis Roche Merck & Co. Sanofi SA Gilead Sciences Johnson & Johnson GlaxoSmithKline AstraZeneca AbbVie Amgen Allergan Teva Pharmaceutical Industries Novo Nordisk Eli Lilly and Co. Bayer Bristol-Myers Squibb Takeda Pharmaceutical Co. Boehringer Ingelheim Astellas Pharma Mylan Laboratories Biogen Idec Celgene Merck KGaA Daiichi Sankyo Valeant Otsuka CSL Baxalta Shire Sun Les Laboratoires Eisal UCB Abbott Fresenius Grifols Chugai CJ (CheilJedang) Mallinckrodt Sumitomo Dainippon Endo Manarini Regeneron Alexion Aspen Mitsubishi Tanabe Nestle Meda Hospira Print Subscribers e-News Subscribers Global HQ Base 2,023 1,073 922 1,357 1,452 706 1,526 1,271 1,858 88 1,085 115 300 151 990 424 1,320 64 853 35 53 422 325 251 12 30 12 23 91 78 89 76 66 37 936 25 10 21 11 8 21 128 15 154 28 36 9 147 28 31 2,571 1,947 2,163 2,706 2,956 881 2,698 2,598 2,652 612 2,145 363 918 284 1,973 1,278 2,590 378 1,551 55 122 1,231 594 287 61 64 60 184 308 257 188 268 312 217 1921 37 23 42 24 19 38 259 33 249 42 105 28 276 60 66 USA Switzerland Switzerland USA France USA USA England England USA USA USA Israel Denmark USA Germany USA Japan Germany Japan USA USA USA Germany Japan Canada Japan Australia USA Ireland India France Japan Belgium USA Germany Spain Japan Korea Ireland Japan Ireland Italy USA USA South Africa Japan Switzerland USA USA Source: PharmaExec.com 9 EDITORIAL PLANNER DATE FOCUS FEATURE SHOW FEATURE January Microbiomics SLAS 2017 February Cell Biology READEX Ad Study March April May June READEX Ad Study September Stem Cells READEX Ad Study Infectious Diseases December 10 December 5 January 6 February 6 March 6 April 6 May 5 June 5 July 7 August 4 September 6 October 6 November 6 SHOW DISTRIBUTION ■■ ■■ ■■ ToxExpo Cancer Research News ■■ ■■ ■■ ■■ AAI ■■ American Association of Immunology ISSCR, ASCO ■■ ■■ ■■ American Society of Clinical Oncology CRISPR Immuno Oncology Summit Cancer Research News ■■ ■■ ■■ Sequencing/GWAS Disease Animal Modeling ■■ ■■ ASHG ■■ Neuroscience READEX Ad Study ■■ Basel Life Science Week SfN October November MATERIALS DATE December 1 January 3 February 1 March 1 April 3 May 1 June 1 July 3 August 1 September 1 October 2 November 1 Molecular Medicine Tri-Conference SLAS 2017 PITTCON ToxExpo BioTherapeutics AACR Experimental Bio AAI PEGS BioMarker Congress ISSCR ASCO World Pharma Congress ASMA Cancer July August SPACE CLOSING January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 DEPARTMENT FOCUS AACR Neuroscience ISSUE DATE ■■ Cancer Research News ASCB Cell Biology Cancer Research News Next Gen Summit Immuno Oncology Summit Discovery On Target BASEL Life Science Week ■■ ASHG ELRIG ■■ Neuroscience (SfN) ■■ ASCB Cell Biology ■■ PepTalk 11 Advertising Rates Rate card #13 NET TABLOID PAGE 1-x 4-x 6-x 8-x 12-x 18-x 24-x Tab Spread $15,810 $14,750 $13,930 $13,280 $12,730 $12,340 $11,930 1/2 Tab Spread $11,810 $11,040 $10,480 $10,020 $9,640 $9,370 $9,070 Tab Page $8,870 $8,500 $8,030 $7,790 $7,480 $7,250 $7,040 1/2 Tab Page $6,910 $6,510 $6,190 $5,920 $5,730 $5,570 $5,410 1/3 Tab Page $5,360 $5,110 $4,850 $4,700 $4,500 $4,400 $4,340 STANDARD PAGE 1-x 4-x 6-x 8-x 12-x 18-x 24-x Standard Spread $13,450 $12,620 $12,010 $11,470 $11,040 $10,750 $10,420 Standard Page $7,480 $6,860 $6,680 $6,410 $6,120 $5,970 $5,860 2/3 Standard Page $6,330 $5,960 $5,680 $5,460 $5,300 $5,150 $5,020 1/2 Standard Page $5,410 $5,090 $4,900 $4,710 $4,580 $4,440 $4,360 1/3 Standard Page $3,400 $3,200 $3,050 $2,920 $2,820 $2,750 $2,660 1/4 Standard Page $2,950 $2,780 $2,640 $2,550 $2,460 $2,400 $2,330 1/6 Standard Page $2,490 $2,360 $2,250 $2,180 $2,100 $2,060 $2,020 PAGE ONE AD* $3,120 $3,120 $3,120 $3,120 $3,120 ---- ---- *Page One Ad (4.75” width x 1.625” height) TERMS AND CONDITIONS: Cancellation of any contract requires 60 days written notice. ALL RATES ARE NET: All rates include 4/color. INSERTS & IMPACT PIECES Net per 4 page insert – Standard supplied $10,380 net 2 page insert – Standard supplied $6,450 net 4 page insert – Standard includes printing $15,840 net 2 page insert – Standard includes printing $10,820 net Full page cover tip on $13,950 net Gatefold – 6 page $33,470 net 12 SPECIAL POSITIONS Earned rate plus Cover 2 15% Cover 3 10% Cover 4 20% Consecutive fraction ads 15% All other guaranteed positions 10% TRADE SHOW FEATURE SPONSORSHIP = $18,000 net Sponsorship includes: Two (2) Print ads (standard or tabloid) within Trade Show Feature, sponsored by logo at top of Show Feature section; Front Page Teaser ad – below what’s new; Digital Edition Sponsorship with custom welcome message and logo, and Pre-Show report eblast to 82,000+ subscribers with exclusive leaderboard and skyscraper banner ads. 13 Production Specs MECHANICAL SPECS ■■ ■■ ■■ BLEEDS width x height (inches) ■■ Tab Page Half Tab–Horiz. 10-7/8 x 14-1/8 bleed 10-5/8 x 13-7/8 trim 10-7/8 x 7-3/16 bleed 10-5/8 x 6-15/16 trim Half Tab–Vert. 5-1/2 x 14-1/8 bleed 5-1/4 x 13-7/8 trim 1/3 Tab–Horiz. 10-7/8 x 5-5/8 bleed 10-5/8 x 5-3/8 trim 1/3 Tab–Vert. 3-9/16 x 14-1/8 bleed 3-5/16 x 13-7/8 trim Tab Spread 21-1/2 x 14-1/8 bleed 21-1/4 x 13-7/8 trim Standard Page Standard Spread NON-BLEEDS Tab Spread Tab Page Half Tab–Horiz. Half Tab–Vert. 1/3 Tab–Horiz. 1/3 Tab–Vert. STANDARD PAGES Spread (non-bleed) Page (non-bleed) 2/3 Page 1/2 Page–Island 1/2 Page–Horiz. 1/2 Page–Vert. 1/3 Page–Vert. 1/3 Page–Square 1/4 Page–Vert. 1/6 Page–Vert. 14 8-3/8 x 10-7/8 bleed 8-1/8 x 10-5/8 trim 16-1/2 x 10-7/8 bleed 16-1/4 x 10-5/8 trim width x height (inches) 20-1/4 x 12-7/8 9-5/8 x 12-7/8 9-5/8 x 6-5/16 4-5/8 x 12-1/2 9-5/8 x 4-7/8 2-13/16 x 12-7/8 width x height (inches) 15 x 10 7 x 10 4-9/16 x 10 4-9/16 x 7-1/2 7 x 4-7/8 3-3/8 x 10 2-3/16 x 10 4-9/16 x 4-7/8 3-3/8 x 4-7/8 2-3/16 x 4-7/8 ■■ ■■ Acceptable digital file formats: PDF or composite TIFF or EPS files with pictures/art and fonts embedded. Bleed ads should have 1/8-inch bleed on all sides and crop marks should be offset by 12 pts. All pictures should be at least 300 dpi at printed size for CMYK and grayscale; 600 dpi for line art. Total ink density not to exceed 260%. 110 line screen. All color is CMYK. PMS or spot colors are not accepted. Please send color proofs at 100%. Without a proof, DDNews cannot be held responsible for the optimum outcome of color. SWOP Standards apply. E-MAIL AD MATERIALS To [email protected] include the advertiser’s name and issue date in the subject line. FTP AD MATERIALS For instructions go to www.ddn-news.com/ftp 2017 Production Schedule ISSUE DATE SPACE CLOSING MATERIALS DATE January 2017 December 1 December 5 February 2017 January 3 January 6 March 2017 February 1 February 6 April 2017 March 1 March 6 May 2017 April 3 April 6 June 2017 May 1 May 5 July 2017 June 1 June 5 August 2017 July 3 July 7 September 2017 August 1 August 4 October 2017 September 1 September 6 November 2017 October 2 October 6 December 2017 November 1 November 6 15 Website videos 3 Month Posting Electronic Advertising Opportunities $2,920 flat Feature Technology Sponsorship 3 Month Minimum $3,200 per month An exclusive sponsorship of all related news articles specific to a “technology” such as qPCR. Included is a 728 x 90 leaderboard, 300 x 250 big box banner, and two product releases which are interspersed within technology editorial. Whitepapers 3 Month Posting $1,830 net (per unit) DDNews website ddn-news.com Various ad sizes are available on the home page and news pages. Ads are placed in rotation. Maximum three deep rotation. Over 60,000 monthly visitors. ADVERTISING RATES (net) Ad Size One Month 3 months per month 6 months per month 12 months per month 300 x 100 $3,070 $2,840 $2,610 $2,160 728 x 90 scrolling banner $3,290 $3,070 $2,840 $2,390 300 x 250 Big Box $4,080 $3,860 $3,630 $3,400 728 x 90 Leaderboard $3,860 $3,180 $2,950 $2,610 REQUIREMENTS: Banners must be in GIF or Animated GIF format only. Banner size as noted above. Banners must be no larger than 20kb in size. No transparent GIF’s or SWF accepted. E-Mail banners to: [email protected] 16 DDNews Cancer website ddncancer.com DDNews is the only news publication to have a dedicated website specifically for cancer research and oncology news. Audience is lab managers, and researchers involved in drug discovery & development for cancer. Over 16,000 monthly visitors. Banners One Month 3 months per month 6 months per month 12 months per month 300 x 100 $2,300 $2,080 $1,860 $1,530 728 x 90 scrolling banner $2,520 $2,300 $2,080 $1,860 300 x 250 Big Box $3,280 $3,060 $2,840 $2,520 728 x 90 Leaderboard $2,950 $2,740 $2,520 $2,300 3 Month Cancer Video Posting $2,300 (net) E-Mail orders to: [email protected] 17 E-Newsletter Our biweekly e-newsletter keeps readers around the world informed of late breaking news, updates, analysis, upcoming industry events, and commentary. Distributed the second and fourth Wednesday of each month to 82,000+ qualified recipients. Custom Content Marketing Combining your news and DDNews to customize your product message. You choose the area of focus/subject (e.g. Cancer, CRISPR, Immunology, etc.) We supply five DDNews stories to fit your subject area; you supply two stories/ product features and your leaderboard banner (468 x 60). We then mail to our 82,000+ qualified recipients, and 20,000 of your customers/ prospects (optional). ADVERTISING RATES (net) Ad Size 1x-5x 6x-11x 12+ 300 x 100 $2,300 $2,080 $1,860 120 x 600 $3,240 $2,950 $2,740 468 x 60 $4,220 $4,010 $3,680 REQUIREMENTS: RATE PER MAILING CCM is available 3 times per month $4500 Leaderboard banner must be static GIF not exceeding 20kb in size. Banners must be in static GIF format only. Banner size as noted above. Banners must be no larger than 20kb in size. No transparent GIF’s or SWF accepted. E-Products & Services Podcasts The DDNews podcast includes: 1. Custom announcement mailing to 82,000+ qualified DDNews recipients and a bonus mailing to 20,000 advertiser supplied contacts (optional). 2. Advertiser receives the “read in” to the podcast, i.e. underwriting credit within the podcast 3. Placement on DDNews website with 20 word description and company logo. 4. It is suggested podcast be formatted as a commentary or a Q&A session. Podcasts content is subject to DDNews editorial approval. Podcast will be recorded as a “Go-to-Meeting” with our production team. Suggested length is 5 – 10 minutes maximum. PODCAST RATES: 1 – 5x 6 – 11x 12x + 18 $4,000 net each $3600 net each $3200 net each February, May, August, November A quarterly showcase of new products and services, available with an optional imbedded three minute video/product demonstration link. Distributed by e-mail to 82,000+ qualified recipients. E-PRODUCTS & SERVICES (per unit) Standard Unit Unit With Video $1,220 (net) $1,930 (net) Custom HTML E-mails Get your product custom message out to the DDNews subscriber. RATES PER MAILING Up to 5,000 $2,910 (net) 5,000 to 6,500 $3,330 (net) 6,500 to 8,000 $3,850 (net) 8,000 to 10,000 $4,370 (net) Mailings larger that 10,000 will be quoted $500 net charge for split copy and/or headline per split. 19 Advertising Sales Representatives NORTHEAST MICHAEL STACK 1127 Kristin Drive, Suite 100, Libertyville, IL 60048 Tel: 847.922.1799 [email protected] MIDWEST/MIDATLANTIC RYAN KING 1900 N. Hudson, #D, Chicago, IL 60614 Tel: 773.414.9292 [email protected] SOUTHWEST HUTSON LAMBERT 212 E. 2nd Street, Suite 202, Pass Christian, MS 39571 Tel:228.452.9683 [email protected] EUROPE, AFRICA, ASIA STEPHANIE PAINTER Painter-Lowe Communications [email protected] www.painter-lowe.com Tel: +44 1634 829386 Management BRUCE POORMAN President & Publisher [email protected] LAURENCE DOYLE Executive VP & General Manager [email protected] MARGE GORSLINE Operations Manager [email protected] DDNews OLD RIVER PUBLICATIONS, LLC. 19035 Old Detroit Road, Suite 203 Rocky River, OH 44116 Tel:440.331.6600 Fax:440.331.7563 www.DDN-news.com